Excellent progress !!!
Celera Corporation (NASDAQ:CRA) a health care company focused on medical therapies, developing dianostic related products has entered in to exclusive licenses agreement to use Cellmid- CDY (previously MTY) patent portfolio for the development of lung cancer diagnostics.
Cellmid Limited (ASX:CDY) is a listed Australian biotechnology company committed to the commercialization of midkine, a heparin-binding growth factor, and its inhibitors for both therapeutic and diagnostic applications.
CDY is actively looking for partners to commercialise the Company’s significant anti-midkine antibody portfolio for diagnostic and therapeutic purposes. In addition, CDY will also be looking for partnerships to continue to research anti-midkine antisense and siRNA.
CDY holds the largest intellectual property portfolio globally in relation to midkine, a significant therapeutic and diagnostic target !!!!!!
Excellent progress !!!Celera Corporation (NASDAQ:CRA) a health...
Add AN1 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.690M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 561500 | 0.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.9¢ | 340000 | 1 |
View Market Depth
| Last trade - 16.12pm 19/07/2024 (20 minute delay) ? |
| AN1 (ASX) Chart |
Day chart unavailable